JP2024536719A5 - - Google Patents
Info
- Publication number
- JP2024536719A5 JP2024536719A5 JP2024514008A JP2024514008A JP2024536719A5 JP 2024536719 A5 JP2024536719 A5 JP 2024536719A5 JP 2024514008 A JP2024514008 A JP 2024514008A JP 2024514008 A JP2024514008 A JP 2024514008A JP 2024536719 A5 JP2024536719 A5 JP 2024536719A5
- Authority
- JP
- Japan
- Prior art keywords
- nrg1
- amino acid
- acid sequence
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10202109667X | 2021-09-03 | ||
| SG10202109667X | 2021-09-03 | ||
| PCT/EP2022/074520 WO2023031435A1 (en) | 2021-09-03 | 2022-09-02 | Treatment and prevention of cancer using her3 antigen-binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536719A JP2024536719A (ja) | 2024-10-08 |
| JP2024536719A5 true JP2024536719A5 (https=) | 2025-09-10 |
Family
ID=83438993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024514008A Pending JP2024536719A (ja) | 2021-09-03 | 2022-09-02 | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250122303A1 (https=) |
| EP (1) | EP4396238A1 (https=) |
| JP (1) | JP2024536719A (https=) |
| KR (1) | KR20240110556A (https=) |
| CN (1) | CN118541395A (https=) |
| TW (1) | TW202328191A (https=) |
| WO (1) | WO2023031435A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4687972A1 (en) | 2023-04-06 | 2026-02-11 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3 antigen-binding molecules |
| CN120446468B (zh) * | 2025-07-07 | 2025-09-26 | 美康生物科技股份有限公司 | 一种血清游离轻链检测试剂及检测方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AR094403A1 (es) * | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| EP3085781A1 (en) | 2013-12-19 | 2016-10-26 | National Cancer Center | Novel fusion gene as factor responsible for stomach cancer |
| IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| EP3679063A4 (en) | 2017-09-08 | 2021-06-02 | The Regents of The University of Colorado, A Body Corporate | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER |
| JP2021534811A (ja) * | 2018-06-22 | 2021-12-16 | シーアールディー ファーマシューティカルズ インコーポレイティド | 抗ｈｅｒ３抗体およびその用途 |
| GB201913079D0 (en) * | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
-
2022
- 2022-09-02 JP JP2024514008A patent/JP2024536719A/ja active Pending
- 2022-09-02 CN CN202280074014.0A patent/CN118541395A/zh active Pending
- 2022-09-02 EP EP22776887.6A patent/EP4396238A1/en active Pending
- 2022-09-02 US US18/688,576 patent/US20250122303A1/en active Pending
- 2022-09-02 TW TW111133471A patent/TW202328191A/zh unknown
- 2022-09-02 KR KR1020247010142A patent/KR20240110556A/ko active Pending
- 2022-09-02 WO PCT/EP2022/074520 patent/WO2023031435A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548057A5 (https=) | ||
| JP2024536719A5 (https=) | ||
| JP2017503480A5 (https=) | ||
| Power et al. | Advanced gastric cancer–slow but steady progress | |
| Monk et al. | Anti-angiogenesis agents in metastatic or recurrent cervical cancer | |
| Xu et al. | MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity | |
| RU2016125551A (ru) | Биспецифические антигенсвязывающие конструкции против her2 | |
| Zhan et al. | Digestive cancers: mechanisms, therapeutics and management | |
| Kuwada et al. | Pro-chemotherapeutic effects of antibody against extracellular domain of claudin-4 in bladder cancer | |
| JP2022533957A5 (https=) | ||
| IL270852A (en) | Molecules that bind at the site of egfr and c – met - fibronectin type iii | |
| del Campo et al. | Update on novel therapeutic agents for cervical cancer | |
| JP2016505537A5 (https=) | ||
| Salati et al. | Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? | |
| JP2008500815A5 (https=) | ||
| RU2010142390A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
| JP7441165B2 (ja) | 抗ｈｅｒ２抗体－薬物コンジュゲート投与によるｈｅｒ２変異がんの治療 | |
| JP2013522237A5 (https=) | ||
| CN105087593A (zh) | 一种her2核酸适配体及其应用 | |
| Businello et al. | Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter | |
| Zhang et al. | Karyopherin β1 deletion suppresses tumor growth and metastasis in colorectal cancer (CRC) by reducing MET expression | |
| JP2023512276A5 (https=) | ||
| RU2015154985A (ru) | Способы лечения рака | |
| JP2024071393A5 (https=) | ||
| RU2019134769A (ru) | Композиции для лечения резистентных к лекарственным средствам опухолей и способы их применения |